1.04

3.70% -0.04

Calcimedica Inc (CALC)

Overview News Price History Financials Discussions Forecast Stock Split

Calcimedica Inc stock is traded at $1.04, with a volume of 13,503. It is down -3.70% in the last 24 hours and down -47.47% over the past month. CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Previous Close:

$1.08

Open:

$1.05

24h Volume:

13,503

Relative Volume:

0.18

Market Cap:

$7.10M

Revenue:

Net Income/Loss:

$-19.54M

P/E Ratio:

-0.7957

EPS:

-1.3071

Net Cash Flow:

$-21.18M

1W Performance:

-18.11%

1M Performance:

-47.47%

6M Performance:

-65.90%

1Y Performance:

-93.60%

1-Day Range:

$1.04

$1.215

1-Week Range:

$1.03

$1.275

52-Week Range:

$1.03

$36.00

Calcimedica Inc Stock (CALC) Company Profile

Name

Calcimedica Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

858-952-5500

Address

505 COAST BOULEVARD SOUTH, LA JOLLA

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

CALC's Discussions on Twitter

Compare CALC vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CALC Calcimedica Inc	1.04	7.10M	0	-19.54M	-21.18M	-1.3071
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Calcimedica Inc Stock (CALC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-26	Initiated	Guggenheim	Buy
Jan-29-26	Downgrade	H.C. Wainwright	Buy → Neutral

Calcimedica Inc Stock (CALC) Latest News

Oct 05, 2026

20,000 director stock options carry a $1.64 exercise price at CalciMedica (CALC). - Stock Titan

Oct 05, 2026

Oct 01, 2026

CalciMedica Establishes $25 Million ATM Stock Program - The Globe and Mail

Oct 01, 2026

Sep 30, 2026

Stock sales may occur from time to time for CalciMedica (CALC) through H.C. Wainwright. - Stock Titan

Sep 30, 2026

Sep 28, 2026

CalciMedica CEO Rachel A. Leheny Awarded 360,000 Stock Options with Four-Year Vesting - Kalkine Media

Sep 28, 2026

At $1.74 a share, CalciMedica (CALC) gives its science chief options to buy 180,000 shares. - Stock Titan

Sep 28, 2026

Sep 17, 2026

CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized - The Globe and Mail

Sep 17, 2026

Sep 16, 2026

Nasdaq $1 listing bar cleared by CalciMedica (NASDAQ: CALC) after earlier deficiency notice - Stock Titan

Sep 16, 2026

Sep 08, 2026

Investors can meet CalciMedica on Sept. 15 - Stock Titan

Sep 08, 2026

Sep 07, 2026